1. Key Insights 2. Heavy Menstrual Bleeding Market Overview at a Glance 2.1. Market Share (%) Distribution of Heavy Menstrual Bleeding in 2017 2.2. Market Share (%) Distribution of Heavy Menstrual Bleeding in 2028 3. Disease Background and Overview: Heavy Menstrual Bleeding 3.1. Introduction 3.2. Causes of HMB 3.3. Polyps 3.4. Myometrial dysfunctions (adenomyosis & leiomyoma) 3.5. Malignancy and hyperplasia 3.6. Coagulopathy 3.7. Ovulatory dysfunction (hormonal causes of HMB) 3.8. Endometrial causes of HMB 3.9. Iatrogenic 3.10. Multiple common pathways that contribute to HMB 3.11. Diagnosis of Heavy menstrual Bleeding 3.12. Differential diagnosis for HMB from structural causes 3.13. Differential diagnosis with disorders of hemostasis and coagulopathy 3.14. NICE Diagnostic guidelines for HMB 4. Epidemiology and Patient Population: Key Findings 4.1. 7MM Total Patient Population of Heavy Menstrual Bleeding 4.2. 7MM Total Diagnosed Patient Population of Heavy Menstrual Bleeding 5. Country Wise-Epidemiology of Heavy Menstrual Bleeding 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Heavy Menstrual Bleeding Prevalent Population in the United States 5.1.3. Uterine Fibroids Prevalent Population in the United States 5.1.4. Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in the United States 5.1.5. Heavy Menstrual Bleeding Diagnosed Prevalent Population in the United States 5.1.6. Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in the United States 5.2. EU5 Countries 5.2.1. Assumptions and Rationale 5.3. Germany 5.3.1. Assumptions and Rationale 5.3.2. Heavy Menstrual Bleeding Prevalent Population in Germany 5.3.3. Uterine Fibroids Prevalent Population in Germany 5.3.4. Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in Germany 5.3.5. Heavy Menstrual Bleeding Diagnosed Prevalent Population in Germany 5.3.6. Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in Germany 5.4. France 5.4.1. Assumptions and Rationale 5.4.2. Heavy Menstrual Bleeding Prevalent Population in France 5.4.3. Uterine Fibroids Prevalent Population in France 5.4.4. Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in France 5.4.5. Heavy Menstrual Bleeding Diagnosed Prevalent Population in France 5.4.6. Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in France 5.5. Italy 5.5.1. Assumptions and Rationale 5.5.2. Heavy Menstrual Bleeding Prevalent Population in Italy 5.5.3. Uterine Fibroids Prevalent Population in Italy 5.5.4. Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in Italy 5.5.5. Heavy Menstrual Bleeding Diagnosed Prevalent Population in Italy 5.5.6. Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in Italy 5.6. Spain 5.6.1. Assumptions and Rationale 5.6.2. Heavy Menstrual Bleeding Prevalent Population in Spain 5.6.3. Uterine Fibroids Prevalent Population in Spain 5.6.4. Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in Spain 5.6.5. Heavy Menstrual Bleeding Diagnosed Prevalent Population in Spain 5.6.6. Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in Spain 5.7. United Kingdom 5.7.1. Assumptions and Rationale 5.7.2. Heavy Menstrual Bleeding Prevalent Population in the United Kingdom 5.7.3. Uterine Fibroids Prevalent Population in the United Kingdom 5.7.4. Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in the United Kingdom 5.7.5. Heavy Menstrual Bleeding Diagnosed Prevalent Population in the United Kingdom 5.7.6. Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in the United Kingdom 5.8. Japan 5.8.1. Assumptions and Rationale 5.8.2. Heavy Menstrual Bleeding Prevalent Population in Japan 5.8.3. Uterine Fibroids Prevalent Population in Japan 5.8.4. Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in Japan 5.8.5. Heavy Menstrual Bleeding Diagnosed Prevalent Population in Japan 5.8.6. Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in Japan 6. Treatment 6.1. Combination hormonal contraceptives 6.2. Progestins 6.2.1. In women with a history of thrombosis who are on anticoagulation 6.2.2. In women with a history of thrombosis who are not on anticoagulation 6.3. NSAID preparations 6.4. Intrauterine system releasing levonorgestrel (LNG) 6.5. Gonadotropin-releasing hormone agonists/antagonists 6.6. Tranexamic acid an anti-Fibrinolytic 6.7. Danazol 6.8. Selective progesterone receptor modulators 6.9. Combined oral contraceptive pill 6.10. Injectable progestogens 6.11. Ulipristal acetate for treatment of uterine fibroids 6.12. Surgical interventions for treatment of heavy menstrual bleeding 6.12.1. Endometrial ablation 6.12.2. Hysterectomy 6.13. Non Hormonal treatment for Anemia caused by HMB 6.14. HMB: The American College of Obstetricians and Gynecologists Recommendations for management of HMB (2019) 6.14.1. Suggestions for Hormonal Medical therapy 6.15. NICE guidelines for management of Heavy Menstrual Bleeding 6.16. Treatment Algorithm 7. Unmet Needs 8. Marketed Drugs 8.1. Lysteda (Tranexamic acid): Ferring Pharmaceuticals 8.1.1. Drug Description 8.1.2. Regulatory Milestones 8.1.3. Other Development Activities 8.1.4. Safety and Efficacy 8.1.5. Product Profile 8.2. Natazia (Estradiol valerate / Dienogest): Bayer 8.2.1. Drug Description 8.2.2. Regulatory Milestones 8.2.3. Other Development Activities 8.2.4. Safety and Efficacy 8.2.5. Product Profile 8.3. Mirena (levonorgestrel-releasing intrauterine system): Bayer 8.3.1. Drug Description 8.3.2. Regulatory Milestones 8.3.3. Other Development Activities 8.3.4. Safety and Efficacy 8.3.5. Product Profile 9. Emerging Drugs 9.1. Key Cross Competition 9.2. Linzagolix (OBE2109): ObsEva 9.2.1. Product Description 9.2.2. Other Developmental Activities 9.2.3. Clinical Development 9.2.4. Product Profile 9.3. Elagolix: AbbVie 9.3.1. Product Description 9.3.2. Other Developmental Activities 9.3.3. Clinical Development 9.3.4. Product Profile 9.4. Relugolix (TAK-385): Myovant Sciences 9.4.1. Product Description 9.4.2. Other Developmental Activities 9.4.3. Clinical Development 9.4.4. Product Profile 9.5. Vilaprisan (BAY1002670): Bayer 9.5.1. Product Description 9.5.2. Clinical Development 9.5.3. Product Profile 9.6. Leuprolide: Enteris BioPharma 9.6.1. Product Description 9.6.2. Clinical Development 9.6.3. Product Profile 10. Heavy Menstrual Bleeding: 7MM Analysis 10.1. Key Findings 10.2. Market Size of Heavy Menstrual Bleeding in the 7MM 10.3. 7MM Market Outlook 10.4. United States Market Size 10.4.1. Total Market size of Heavy Menstrual Bleeding 10.4.2. Market Size by Therapies 10.5. Germany Market Size 10.5.1. Total Market size of Heavy Menstrual Bleeding in Germany 10.5.2. Market Size by Therapies 10.6. France Market Size 10.6.1. Total Market Size of Heavy Menstrual Bleeding 10.6.2. Market Size by Therapies 10.7. Italy Market Size 10.7.1. Total Market Size of Heavy Menstrual Bleeding 10.7.2. Market Size by Therapies 10.8. Spain Market Size 10.8.1. Total Market Size of Heavy Menstrual Bleeding 10.8.2. Market Size by Therapies 10.9. United Kingdom Market Size 10.9.1. Total Market Size of Heavy Menstrual Bleeding 10.9.2. Market Size by Therapies 10.10. Japan market Size 10.10.1. Total Market Size of Heavy Menstrual Bleeding 10.10.2. Market Size by Therapies 11. Case Reports 11.1. Patient-reported prevalence and symptomatic burden of uterine fibroids among women in the United States: findings from a cross-sectional survey analysis 11.2. Symptoms of uterine myomas: data of an epidemiological study in Germany 11.3. Burden of uterine fibroids in Italy: epidemiology, treatment outcomes, and consumption of health care resources in more than 5,000 women 11.4. Treatment patterns and health care resource utilization and costs in heavy menstrual bleeding: a Japanese claims database analysis 12. Market Drivers 13. Market Barriers 14. Appendix 14.1. Bibliography 14.2. Report Methodology 15. DelveInsight Capabilities 16. Disclaimer 17. About DelveInsight

Table 1: Total Population of Heavy Menstrual Bleeding in the 7MM (2017–2028) Table 2: Total Diagnosed Population of Heavy Menstrual Bleeding in the 7MM (2017–2028) Table 3: Heavy Menstrual Bleeding Prevalent Population in the United States (2017–2028) Table 4: Uterine Fibroids Prevalent Population in the United States (2017–2028) Table 5: Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in the United States (2017–2028) Table 6: Heavy Menstrual Bleeding Diagnosed Prevalent Population in the United States (2017–2028) Table 7: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population patients in the United States (2017–2028) Table 8: Heavy Menstrual Bleeding Prevalent Population in Germany (2017–2028) Table 9: Uterine Fibroids Prevalent Population in Germany (2017–2028) Table 10: Heavy Menstrual Bleeding Prevalent Population due to Uterine Fibroids in Germany (2017–2028) Table 11: Heavy Menstrual Bleeding Diagnosed Prevalent Population in Germany (2017–2028) Table 12: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in Germany (2017–2028) Table 13: Heavy Menstrual Bleeding Prevalent Population in France (2017–2028) Table 14: Uterine Fibroids Prevalent Population in France (2017–2028) Table 15: Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in France (2017–2028) Table 16: Heavy Menstrual Bleeding Diagnosed Prevalent Population in France (2017–2028) Table 17: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in France (2017–2028) Table 18: Heavy Menstrual Bleeding Prevalent Population in Italy (2017–2028) Table 19: Uterine Fibroids Prevalent Population in Italy (2017–2028) Table 20: Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in Italy (2017–2028) Table 21: Heavy Menstrual Bleeding Diagnosed Prevalent Population in Italy (2017–2028) Table 22: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in Italy (2017–2028) Table 23: Heavy Menstrual Bleeding Prevalent Population in Spain (2017–2028) Table 24: Uterine Fibroids Prevalent Population in Spain (2017–2028) Table 25: Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in Spain (2017–2028) Table 26: Heavy Menstrual Bleeding Diagnosed Prevalent Population in Spain (2017–2028) Table 27: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in Spain (2017–2028) Table 28: Heavy Menstrual Bleeding Prevalent Population in the United Kingdom (2017–2028) Table 29: Uterine Fibroids Gender-wise Prevalent Population in the United Kingdom (2017–2028) Table 30: Heavy Menstrual Bleeding Prevalent Population due to Uterine Fibroids in the United Kingdom(2017–2028) Table 31: Heavy Menstrual Bleeding Diagnosed Prevalent Population in the United Kingdom (2017–2028) Table 32: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in the United Kingdom (2017–2028) Table 33: Heavy Menstrual Bleeding Prevalent Population in Japan (2017–2028) Table 34: Uterine Fibroids Prevalent Population in Japan (2017–2028) Table 35: Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in Japan(2017–2028) Table 36: Heavy Menstrual Bleeding Diagnosed Prevalent Population in Japan (2017–2028) Table 37: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in Japan (2017–2028) Table 38: Medical treatment regimens for acute Heavy Menstrual Bleeding Table 39: Comparison of Emerging Drugs Under Development Table 40: Linzagolix (OBE2109), Clinical Trial Description Table 41: Elagolix, Clinical Trial Description Table 42: Relugolix, Clinical Trial Description Table 43: Vilaprisan, Clinical Trial Description Table 44: Leuprolide, Clinical Trial Description Table 45: Seven Major Market Size of Heavy Menstrual Bleeding in USD Million (2017–2028) Table 46: United States Market Size of Heavy Menstrual Bleeding , USD Million (2017–2028) Table 47: Market size of Heavy Menstrual Bleeding by therapies in the United States, in USD Million (2017–2028) Table 48: Market Size of Heavy Menstrual Bleeding in Germany, in USD Million (2017–2028) Table 49: Market size of Heavy Menstrual Bleeding by therapies in Germany, in USD Million (2017–2028) Table 50: Market Size of Heavy Menstrual Bleeding in France, in USD Million (2017–2028) Table 51: Market size of Heavy Menstrual Bleeding by therapies in France, in USD Million (2017–2028) Table 52: Market Size of Heavy Menstrual Bleeding in Italy, in USD Million (2017–2028) Table 53: Market size of Heavy Menstrual Bleeding by therapies in Italy, in USD Million (2017–2028) Table 54: Market Size of Heavy Menstrual Bleeding in Spain, in USD Million (2017–2028) Table 55: Market size of Heavy Menstrual Bleeding by therapies in Spain, in USD Million (2017–2028) Table 56: Market Size of Heavy Menstrual Bleeding in the UK, in USD Million (2017–2028) Table 57: Market size of Heavy Menstrual Bleeding by therapies in the United Kingdom, in USD Million (2017–2028) Table 58: Market Size of Heavy Menstrual Bleeding in Japan, in USD Million (2017–2028) Table 59: Market size of Heavy Menstrual Bleeding by therapies in Japan, in USD Million (2017–2028) Figure 1: Pathways that contribute to HMB Figure 2: Diagnosis of heavy menstrual bleeding Figure 3: Total Patient Population of Heavy Menstrual Bleeding in the 7MM (2017–2028) Figure 4: Total Diagnosed Patient Population of Heavy Menstrual Bleeding in the 7MM (2017–2028) Figure 5: Heavy Menstrual Bleeding Prevalent Population in the United States (2017–2028) Figure 6: Uterine Fibroids Prevalent Population in the United States (2017–2028) Figure 7: Heavy Menstrual Bleeding due to Uterine Prevalent Population Fibroids in the United States (2017–2028) Figure 8: Heavy Menstrual Bleeding Diagnosed Prevalent Population in the United States (2017–2028) Figure 9: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in the United States (2017–2028) Figure 10: Heavy Menstrual Bleeding Prevalent Population in Germany (2017–2028) Figure 11: Uterine Fibroids Prevalent Population in Germany (2017–2028) Figure 12: Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in Germany (2017–2028) Figure 13: Heavy Menstrual Bleeding Diagnosed Prevalent Population in Germany (2017–2028) Figure 14: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in Germany (2017–2028) Figure 15: Heavy Menstrual Bleeding Prevalent Population in France (2017–2028) Figure 16: Uterine Fibroids Prevalent Population in France (2017–2028) Figure 17: Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in France (2017–2028) Figure 18: Heavy Menstrual Bleeding Diagnosed Prevalent Population in France (2017–2028) Figure 19: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in France (2017–2028) Figure 20: Heavy Menstrual Bleeding Prevalent Population in Italy (2017–2028) Figure 21: Uterine Fibroids Prevalent Population in Italy (2017–2028) Figure 22: Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in Italy (2017–2028) Figure 23: Heavy Menstrual Bleeding Diagnosed Prevalent Population in Italy (2017–2028) Figure 24: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in Italy (2017–2028) Figure 25: Heavy Menstrual Bleeding Prevalent Population in Spain (2017–2028) Figure 26: Uterine Fibroids Prevalent Population in Spain (2017–2028) Figure 27: Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in Spain (2017–2028) Figure 28: Heavy Menstrual Bleeding Diagnosed Prevalent Population in Spain (2017–2028) Figure 29: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in Spain (2017–2028) Figure 30: Heavy Menstrual Bleeding Prevalent Population in the United Kingdom (2017–2028) Figure 31: Uterine Fibroids Prevalent Population in the United Kingdom (2017–2028) Figure 32: Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in the United Kingdom (2017–2028) Figure 33: Heavy Menstrual Bleeding Diagnosed Prevalent Population in the United Kingdom (2017–2028) Figure 34: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in the United Kingdom (2017–2028) Figure 35: Heavy Menstrual Bleeding Prevalent Population in Japan (2017–2028) Figure 36: Uterine Fibroids Prevalent Population in Japan (2017–2028) Figure 37: Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in Japan (2017–2028) Figure 38: Heavy Menstrual Bleeding Diagnosed Prevalent Population in Japan (2017–2028) Figure 39: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in Japan (2017–2028) Figure 40: Synthesis and signalling of prostaglandins Figure 41: The fibrinolytic pathway Figure 42: Treatment Algorithm for HMB. Figure 43: Unmet Needs of HMB Figure 44: Seven Major Market Size of Heavy Menstrual Bleeding in USD Million (2017–2028) Figure 45: Market Size of Heavy Menstrual Bleeding in the United States, USD Millions (2017–2028) Figure 46: Market size of Heavy Menstrual Bleeding by therapies in the US, in USD Million (2017–2028) Figure 47: Market Size of Heavy Menstrual Bleeding in Germany, USD Million (2017–2028) Figure 48: Market Size of Heavy Menstrual Bleeding by therapies, in Germany, in USD Million (2017–2028) Figure 49: Market Size of Heavy Menstrual Bleeding in France, USD Million (2017–2028) Figure 50: Market Size of Heavy Menstrual Bleeding by therapies, in France, in USD Million (2017–2028) Figure 51: Market Size of Heavy Menstrual Bleeding in Italy, USD Million (2017–2028) Figure 52: Market Size of Heavy Menstrual Bleeding by therapies, in Italy, in USD Million (2017–2028) Figure 53: Market Size of Heavy Menstrual Bleeding in Spain, USD Million (2017–2028) Figure 54: Market Size of Heavy Menstrual Bleeding by therapies in Spain, in USD Million (2017–2028) Figure 55: Market Size of Heavy Menstrual Bleeding in the UK, USD Million (2017–2028) Figure 56: Market Size of Heavy Menstrual Bleeding by therapies in the UK, in USD Million (2017–2028) Figure 57: Market Size of Heavy Menstrual Bleeding in Japan, USD Million (2017–2028) Figure 58: Market Size of Heavy Menstrual Bleeding by therapies in Japan, in USD Million (2017–2028) Figure 59: Market Drivers Figure 60: Market Barriers

Ferring Pharmaceuticals ObsEva AbbVie Myovant Sciences Bayer Enteris BioPharma